Adicet Bio, Inc. (ACET) intrinsic value & 10-year financials
Adicet Bio, Inc. (ACET) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.57
- Market cap
- $31.5M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 32.2%
- ROIC (10-yr avg)
- -117.3%
- Free cash flow (FY2025)
- -$97.0M
ACET 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$116.8M | -$16.95 | -$97.0M | — | -88.5% |
| FY2024 | — | -$117.1M | -$1.33 | -$93.5M | — | -148.1% |
| FY2023 | — | -$142.7M | -$1.66 | -$98.2M | — | -373.6% |
| FY2022 | $25.0M | -$69.8M | -$0.85 | -$61.5M | -290.3% | -147.8% |
| FY2021 | $9.7M | -$62.0M | -$1.00 | -$64.1M | -631.4% | -134.9% |
| FY2020 | $17.9M | -$36.7M | — | -$42.5M | -218.9% | -79.3% |
| FY2019 | $995.0K | -$82.7M | — | -$74.0M | -8588.6% | -91.9% |
| FY2018 | $8.2M | -$37.6M | — | -$35.9M | -485.3% | -109.9% |
| FY2017 | — | -$33.8M | — | -$11.0M | — | 118.3% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Adicet Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Adicet Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -100.4% ROIC.
Adicet Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Adicet Bio, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-563.01 per share.